FindTrial
Sign In

CDK4/6 inhibitor

DRUG10 trials

Sponsors

Royal Marsden NHS Foundation Trust, First Affiliated Hospital Xi'an Jiaotong University, RenJi Hospital, Fudan University, Ain Shams University

Conditions

Adjuvant TherapyAdvanced Breast CancerBreast CancerER+ Breast CancerHER2+ Breast CancerHR+/HER2- Breast CancerMetastatic Breast CancerProgression, Disease

Phase 2

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Active, not recruitingNCT04920708
Royal Marsden NHS Foundation TrustAdvanced Breast Cancer, ER+ Breast Cancer, Metastatic Breast Cancer
Start: 2022-12-28End: 2027-06-01Updated: 2026-04-14
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
RecruitingNCT07117630
Fudan UniversityBreast Cancer
Start: 2025-09-25End: 2027-08-01Target: 40Updated: 2026-05-19
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
RecruitingNCT07180160
Wenjin YinAdvanced Breast Cancer
Start: 2025-09-25End: 2028-03-31Target: 123Updated: 2025-11-18
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Not yet recruitingNCT07527806
Peking University Cancer Hospital & InstituteBreast Cancer
Start: 2026-05-01End: 2029-12-31Target: 156Updated: 2026-04-17

Phase 3

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
NCT05429684
First Affiliated Hospital Xi'an Jiaotong UniversityHER2+ Breast Cancer
Start: 2021-01-01End: 2024-02-28Target: 120Updated: 2022-06-23
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
RecruitingNCT06447623
Fudan UniversityAdvanced Breast Cancer, HR+/HER2- Breast Cancer
Start: 2024-02-01End: 2029-02-01Target: 184Updated: 2024-06-07
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer
Not yet recruitingNCT07005557
Fudan UniversityAdjuvant Therapy, Breast Cancer
Start: 2025-06-15End: 2035-05-15Target: 1244Updated: 2025-06-05

Unknown Phase

CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
RecruitingNCT05795335
RenJi HospitalBreast Cancer
Start: 2023-04-30End: 2028-12-30Target: 172Updated: 2023-05-16
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy
CompletedNCT06558084
Ain Shams UniversityProgression, Disease, Toxicity, Drug
Start: 2022-07-06End: 2024-08-10Updated: 2024-08-16
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
RecruitingNCT07180056
Wenjin YinBreast Cancer
Start: 2025-08-28End: 2033-02-28Target: 229Updated: 2025-11-19

Related Papers

Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).
Journal of Clinical Oncology2023-06-012 citations